Summary

Row

Number of studies

25

Number of epitopes

843

Number of HLA alleles

60

Row

Epitope-HLA pairs per study

Distinct HLA(s) associated with epitopes

Epitopes per HLA

Protein coverage

Row

Epitopes per protein

S protein coverage

E protein coverage

M protein coverage

N protein coverage

ORF1a protein coverage

ORF1b protein coverage

ORF3a protein coverage

ORF6 protein coverage

ORF7a protein coverage

ORF8 protein coverage

Response frequency

Row

Response frequency (overall) vs studies (count)

Global population coverage and conservation

Row

Conservation vs Estimated population coverage (Conservation among 1,462,390 SARS-CoV-2 sequences)

SARS-CoV-2 epitopes (overall)

SARS-CoV-2 epitopes (per study)

HLA augmentation using SARS-CoV data

SARS-CoV-2 immunogenic peptides

SARS-CoV-2 epitopes from animal studies

About

Last updated on May 30, 2021.

How to cite

A. A. Quadeer, S. F. Ahmed, and M. R. McKay, “Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform,” Cell Reports Medicine, 2021.

Previous version (updated April 20, 2021) .

References

  1. Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan, N., Linster, M., et al. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462.

  2. Chour, W., Xu, A.M., Ng, A.H.C., Choi, J., Xie, J., Yuan, D., Lee, J.K., Delucia, D.C., Edmark, R., Jones, L., et al. (2020). Shared antigen-specific CD8+ T cell responses against the SARS-COV-2 spike protein in HLA A*02:01 COVID-19 participants. MedRxiv 2020.05.04.20085779.

  3. Ferretti, A.P., Kula, T., Wang, Y., Nguyen, D.M.V., Weinheimer, A., Dunlap, G.S., Xu, Q., Nabilsi, N., Perullo, C.R., Cristofaro, A.W., et al. (2020). Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike Protein. Immunity 53, 1095-1107.e3.

  4. Habel, J.R., Nguyen, T.H.O., van de Sandt, C.E., Juno, J.A., Chaurasia, P., Wragg, K., Koutsakos, M., Hensen, L., Jia, X., Chua, B., et al. (2020). Suboptimal SARS-CoV-2−specific CD8 + T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl. Acad. Sci. 117, 24384–24391.

  5. Hu, C., Shen, M., Han, X., Chen, Q., Li, L., Chen, S., Zhang, J., Gao, F., Wang, W., Wang, Y., et al. (2020). Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants. BioRxiv 2020.11.02.364729.

  6. Kared, H., Redd, A.D., Bloch, E.M., Bonny, T.S., Sumatoh, H., Kairi, F., Carbajo, D., Abel, B., Newell, E.W., Bettinotti, M.P., et al. (2021). SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19 individuals. J. Clin. Invest. 131.

  7. Lee, E., Sandgren, K., Duette, G., Stylianou, V. V., Khanna, R., Eden, J.-S., Blyth, E., Gottlieb, D., Cunningham, A.L., and Palmer, S. (2020). Identification of SARS-CoV-2 nucleocapsid and spike T-cell epitopes for assessing T-cell immunity. J. Virol. JVI.02002-20.

  8. Nelde, A., Bilich, T., Heitmann, J.S., Maringer, Y., Salih, H.R., Roerden, M., Lübke, M., Bauer, J., Rieth, J., Wacker, M., et al. (2021). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74–85.

  9. Nielsen, S.S.F., Vibholm, L.K., Monrad, I., Olesen, R., Frattari, G.S., Pahus, M.H., Højen, J.F., Gunst, J.D., Erikstrup, C., Holleufer, A., et al. (2020). SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. BioRxiv 2020.10.08.331645.

  10. Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020). Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345.

  11. Poran, A., Harjanto, D., Malloy, M., Arieta, C.M., Rothenberg, D.A., Lenkala, D., van Buuren, M.M., Addona, T.A., Rooney, M.S., Srinivasan, L., et al. (2020). Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes. Genome Med. 12, 70.

  12. Rha, M.-S., Jeong, H.W., Ko, J.-H., Choi, S.J., Seo, I.-H., Lee, J.S., Sa, M., Kim, A.R., Joo, E.-J., Ahn, J.Y., et al. (2021). PD-1-expressing SARS-CoV-2-specific CD8+ T cells are not exhausted, but functional in patients with COVID-19. Immunity 54, 44-52.e3.

  13. Saini, S.K., Hersby, D.S., Tamhane, T., Povlsen, H.R., Hernandez, S.P.A., Nielsen, M., Gang, A.O., and Hadrup, S.R. (2021). SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients. Sci. Immunol. Vol. 6, Issue 58.

  14. Schulien, I., Kemming, J., Oberhardt, V., Wild, K., Seidel, L.M., Killmer, S., Sagar, Daul, F., Salvat Lago, M., Decker, A., et al. (2020). Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nat. Med.

  15. Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020). Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158-168.e14.

  16. Shomuradova, A.S., Vagida, M.S., Sheetikov, S.A., Zornikova, K. V., Kiryukhin, D., Titov, A., Peshkova, I.O., Khmelevskaya, A., Dianov, D. V., Malasheva, M., et al. (2020). SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors. Immunity 53, 1245-1257.e5.

  17. Snyder, T.M., Gittelman, R.M., Klinger, M., May, D.H., Osborne, E.J., Taniguchi, R., Zahid, H.J., Kaplan, I.M., Dines, J.N., Noakes, M.N., et al. (2020). Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels. MedRxiv 2020.07.31.20165647.

  18. Tarke, A., Sidney, J., Kidd, C.K., Dan, J.M., Ramirez, S.I., Yu, E.D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P., et al. (2021). Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reports Med. 2, 100204.

  19. A. A. Quadeer, S. F. Ahmed, and M. R. McKay (2020). Epitopes targeted by T cells in convalescent COVID-19 patients bioRxiv 10.1101/2020.08.26.267724v2.

  20. Lineburg, K.E., Grant, E.J., Swaminathan, S., Chatzileontiadou, D.S.M., Szeto, C., Sloane, H., Panikkar, A., Raju, J., Crooks, P., Rehan, S., et al. (2021). CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity.